Maleimide chemistry is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
The idea that Germany had lost the war because its scientists were morally superior was as outrageous as it was unbelievable, but struck a chord in postwar German academe. It infuriated Goudsmit, whose parents had been murdered in Auschwitz. On 3 January 1946, six months after they had arrived at Farm Hall, the group was allowed to return to Germany. Hahn, Heisenberg, von Laue and von Weizsäcker were brought to Göttingen, which was controlled by the British occupation authorities.
== Limits == Each individual is born with a particular range of motion for each joint in their body. In the 1964 book Finding Balance by Gigi Berardi, the author mentions three limiting factors: occupational demands, movement demands, and training oversights.
medical physicists and biochemists) for medical research projects, but it is becoming clear that it also has the ability to give doctors useful clinical information, especially with the discovery that it can be used to probe the concentration of alpha-Hydroxyglutaric acid, which is only present in IDH1 and IDH2 mutated gliomas, which alters the prescribed treatment regimen. MRS is currently used to investigate a number of diseases in the human body, most notably cancer (in brain, breast and prostate), epilepsy, Alzheimer's disease, Parkinson's disease, and Huntington's chorea. MRS has been used to diagnose pituitary tuberculosis. Prostate cancer: Combined with a magnetic resonance imaging (MRI) and given equal results, then the three-dimensional MRS can predict the prevalence of a malignant degeneration of prostate tissue by approximately 90%. The combination of both methods may be helpful in the planning of biopsies and therapies of the prostate, as well as to monitor the success of a therapy.
=== Regional government === The North East Combined Authority is a strategic authority established in 2024. It provides a forum for Tyne and Wear's five metropolitan borough councils to collaborate with each other, Northumberland County Council, and Durham County Council. The authority has eight voting and two non-voting members. The voting members are a directly elected mayor and one councillor appointed by each of the member councils, and the non-voting members are appointed by the combined authority to represent the interests of the business sector and the voluntary sector respectively. Since the 2024 North East mayoral election the mayor has been Kim McGuinness of the Labour Party. Nexus, the passenger transport executive for Tyne and Wear, is an executive body of the combined authority. It is responsible for many aspects of public transport within the county, for example the Tyne and Wear Metro.
Sources: en.wikipedia.org
=== Legal status === In December 2016, a new drug application was filed with the US Food and Drug Administration (FDA), and in October 2017, an FDA advisory committee approved it unanimously. In December 2017, the injectable version with the brand name Ozempic was approved in the US for use by people with diabetes, and, in January 2018, in Canada. In February 2018, authorization was granted in the European Union, in March 2018 in Japan, and in August 2019 in Australia. A version of semaglutide to treat diabetes that can be taken orally (Rybelsus) was approved for medical use in the US in September 2019, and in the European Union in April 2020. In January 2023, the US FDA prescription label for Rybelsus was updated to reflect that it can be used as a first-line treatment for adults with type 2 diabetes. In June 2021, a higher-dose version for injectable use, sold under the brand name Wegovy, was approved by the FDA as an anti-obesity medication for long-term weight management in adults. In January 2022, Wegovy was approved for medical use in the European Union. In December 2025, an oral version of semaglutide, sold under the brand name Wegovy, was approved in the US for weight management. In March 2026, the CHMP recommended granting a conditional marketing authorization for Kayshild (semaglutide), a GLP-1 receptor agonist for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis, a serious disease where fat deposits accumulate in the liver causing inflammation.
=== MSNovelist: De novo structure prediction === MSNovelist is a computational method for the de novo generation of small molecule structures. It addresses a key limitation of database search tools, which can only identify compounds already present in reference structure databases. This makes it particularly useful for analyzing poorly represented analyte classes and novel compounds. It is not intended to replace database searches altogether, but generates structures which can serve as a great starting point for elucidation of specific unknowns. MSNovelist functions by generating novel molecular structures based on the molecular formula (identified by SIRIUS) and the molecular fingerprint (predicted by CSI:FingerID) of the unknown compound. An encoder–decoder recurrent neural network (RNN) model is trained to translate the input fingerprint into a structure, represented as a SMILES sequence, under the constraints of the predicted molecular formula. MSNovelist generates multiple candidate structures from the predicted molecular fingerprint. Once the candidate structures are generated, they are ranked using CSI:FingerID.
Diabetes, Obesity and Metabolism is a monthly peer-reviewed medical journal established in 1999 covering research on diabetes, obesity, and metabolism. The journal has a 2024 Clarivate impact factor of 5.7. The journal publishes on topics such as pharmacokinetics and pharmacodynamics, cost-effectiveness, real world evidence of drug utilisation, safety and effectiveness, as well as conventional randomized controlled trials (phase I-IV studies).
== Diagnosis == Since arteritic AION is similar in presentation to non-arteritic AION, patients over the age of 50 diagnosed with NAION must be evaluated to exclude AAION (symptoms: painful jaw muscle spasms, scalp tenderness, unintentional weight loss, fatigue, myalgias and loss of appetite); NAION patients over the age of 75 should always be tested. The distinction between AAION and non-arteritic AION was made to highlight the different etiologies of anterior ischemic optic neuropathy. AAION is due to temporal arteritis (also called giant-cell arteritis), an inflammatory disease of medium-sized blood vessels (Chapel-Hill-Conference) that occurs especially with advancing age. In contrast, NAION results from the coincidence of cardiovascular risk factors in a patient with "crowded" optic discs. Non-arteritic AION is more common than AAION and usually occurs in slightly younger persons. While only a few cases of NAION result in near total loss of vision, most cases of AAION result in nearly complete vision loss. Nonarteritic anterior ischemic optic neuropathy is an isolated white-matter stroke of the optic nerve (ON). NAION is the most common cause of sudden optic nerve-related vision loss, affecting more than 10,000 Americans every year, often bilaterally. No clinically effective treatments exist, largely because little is known about its pathophysiology, and there are few histopathological studies of the acute condition.
=== Lyophilization === If the solution doesn't contain any other soluble component than the protein in question the protein can be lyophilized (dried). This is commonly done after an HPLC run. This simply removes all volatile components, leaving the proteins behind.
Sources: en.wikipedia.org
Brachytherapy is used to place a sealed radioactive source inside or near the body to treat cancer, such as prostate cancer. Afterloading brachytherapy is often combined with teletherapy, which is external radiation delivered from a greater distance than brachytherapy. It is not classified as a nuclear medicine procedure, although like nuclear medicine, it uses the radiation emitted by radionuclides. After initial interest in brachytherapy in the early 20th century, its use declined in the mid-20th century because of the radiation exposure to physicians from manual handling of the radiation sources. It was not until the development of remote-controlled afterloading systems and the use of new radiation sources in the 1950s and 1960s that the risk of unnecessary radiation exposure to physicians and patients was reduced. In the afterloading procedure, an empty, tubular applicator is inserted into the target volume (e.g., the uterus) before the actual therapy and, after checking the position, loaded with a radioactive preparation. The preparation is located at the tip of a steel wire that is advanced and retracted step by step under computer control. After the pre-calculated time, the source is withdrawn into a safe and the applicator is removed. The procedure is used for breast cancer, bronchial carcinoma or oral floor carcinoma, among others. Beta emitters such as 90Sr or 106Ru or 192Ir are used.
== Key techniques and innovations == Advanced emerging technologies in proteomics profiling are revolutionizing sensitivity, speed, and data analysis capabilities. Some key milestones in advances have been:
Refined sugar is made from raw sugar that has undergone a refining process to remove the molasses. Raw sugar is sucrose which is extracted from sugarcane or sugar beet. While raw sugar can be consumed, the refining process removes unwanted tastes and results in refined sugar or white sugar. The sugar may be transported in bulk to the country where it will be used and the refining process often takes place there. The first stage is known as affination and involves immersing the sugar crystals in a concentrated syrup that softens and removes the sticky brown coating without dissolving them. The crystals are then separated from the liquor and dissolved in water. The resulting syrup is treated either by a carbonatation or by a phosphatation process. Both involve the precipitation of a fine solid in the syrup and when this is filtered out, many of the impurities are removed at the same time. Removal of colour is achieved by using either a granular activated carbon or an ion-exchange resin. The sugar syrup is concentrated by boiling and then cooled and seeded with sugar crystals, causing the sugar to crystallise out. The liquor is spun off in a centrifuge and the white crystals are dried in hot air and ready to be packaged or used. The surplus liquor is made into refiners' molasses. The International Commission for Uniform Methods of Sugar Analysis sets standards for the measurement of the purity of refined sugar, known as ICUMSA numbers; lower numbers indicate a higher level of purity in the refined sugar. Refined sugar is widely used for industrial needs for higher quality.
Following his trial and conviction at Bristol Crown Court, Darren Osment, 40, is sentenced to life imprisonment with a minimum of 20 years for the 2012 murder of his partner, Claire Holland, 32, whose body has never been found. Following a trial at Birmingham Crown Court, Kian Durnin, Martinho De-Sousa, and Tireq McIntosh, are each sentenced to 23 years in prison for their part in a shooting attack at a Wolverhampton park during which two children were injured. 21 December – The UK government confirms that British Sign Language will be taught at GCSE level in England from September 2025. 22 December – Secretary of State for Transport Mark Harper announces that regulated train fares in England will rise by 4.9% from March 2024. 23 December – Rebecca Welch becomes the first female referee to officiate at a Premier League match as Fulham play Burnley at Craven Cottage. 24 December – A 22-year-old woman is stabbed to death during an incident in Bermondsey, south London. A 16-year-old boy is subsequently arrested on suspicion of murder. 26 December – Sam Allison becomes the first black referee to take charge of a Premier League match for 15 years when he officiates at Sheffield United's game against Luton Town. 27 December – A murder investigation is under way after a car struck a crowd of people outside a property in Sheffield, South Yorkshire, killing a 40-year-old man. 28 December – Three men are drowned after a 4x4 vehicle plunges into the River Esk in North Yorkshire.
Notably, targeted proteomics shows increased reproducibility and repeatability compared with shotgun methods, although at the expense of data density and effectiveness. Data quality. Proteomic analysis is highly amenable to automation and large data sets are created, which are processed by software algorithms. Filter parameters are used to reduce the number of false hits, but they cannot be eliminated. Scientists have expressed the need for awareness that proteomics experiments should adhere to the criteria of analytical chemistry (sufficient data quality, sanity check, validation).
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.